A Study of PF-07799544 and PF-07799933 for Advanced Solid Tumors with BRAF V600 Mutation
This study is looking into the safety and effects of two medicines, PF-07799544 and PF-07799933, taken together as a potential treatment for adults with advanced solid tumors. You might be able to join if you have certain advanced cancers like melanoma, glioma, thyroid cancer, or non-small cell lung cancer that have spread or come back. A key requirement is that your tumor must have a specific genetic change called a "BRAF V600 mutation." You would have also received prior cancer treatments. The main goals are to see how safe the medicines are and what side effects they might cause.
- Study design
- This is an interventional study, meaning you will receive the study medicines. It is a Phase 1b study, focusing on the combination of PF-07799544 and PF-07799933, and plans to enroll 124 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for side effects from the start of treatment until 28 days after your last dose of study medication.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
At a glance
Conditions
Where it's being run
83 sites across 32 statesStudy leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with dose limiting toxicities (DLTs)Cycle 1 (21 days)
DLTs will be evaluated during the first cycle (21 days) as a single agent (phase 1a monotherapy) or in combination with other agents (phase 1b dose escalation)
- Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with treatment-emergent adverse events (AEs)Baseline to 28 days after last dose of study medication
AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy
- Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in laboratory abnormalitiesBaseline to 28 days after last dose of study treatment
Laboratory abnormalities as characterized by type, frequency, severity, and timing.
- Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in vital sign abnormalitiesBaseline to 28 days after last dose of study treatment
Vital sign abnormalities as characterized by type, frequency, severity, and timing.
- Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in physical exam abnormalitiesBaseline to 28 days after last dose of study treatment
Physical exam abnormalities as as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
- Phase 1b Dose Expansion: Overall response rate (ORR)Baseline to 2 years
Response will be evaluated via radiographical tumor assessments by RECIST v1.1 for solid tumors or RANO for primary brain tumors